New Phase III data for Novartis’ Menveo show that the vaccine produced a greater immune response against meningococcal serogroups A, C, W-135 and Y in adolescents 11-18 years of age compared to Sanofi Pasteur’s Menactra. Infection with any of these four vaccine-preventable serogroups can lead to bacterial meningitis, an infection of the membrane around the brain and spinal cord, or sepsis, a serious infection of the blood stream. Menveo is an investigational quadrivalent meningococca...